Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Polyrizon Ltd. (PLRZ)
USD13.07
-0.69 (-4.98%)
IL NASDAQ Healthcare Biotechnology
Address
5 Ha-Tidhar Street 4366507
Ra'anana, IL
Ra'anana, IL
CEO
Tomer Izraeli
Website
polyrizon-biotech.com
IPO
2024-10-29
CIK 1893645 ISIN IL0011814113
Description
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD13.07
-0.69 (-4.98%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
45.7K
Beta
-1.53
Float Shares
1.05M
Free Float %
93.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.06% | +12.96% | +7.99% | +37.47% | +434.89% | +102.24% | +272.45% | -99.26% | -99.26% | -99.26% | -99.26% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
13.07
DCF (Unlevered)
0.81
-93.8%
DCF (Levered)
0.81
-93.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
25.47
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+98.5% ★ Q4'25: +94.6% (vs Q3'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-71.7% Q4'25: -172.6% (vs Q3'24)
-
Share dilution Biotechnology: -3.4%+13,341.4% Q4'25: +11,801.6% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: 0.00× (vs Q3'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
2
Total invested
13.4K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q3
Investors holding
2
-2 vs prev Q
New positions
0
Closed positions
2
Increased
0
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | CITIGROUP INC | — -115.0 (-100.0%) | — -124.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 2 | UBS GROUP AG | — -12.3K (-100.0%) | — -13.2K (-100.0%) | 0.00% -0.142 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
6
Shares acquired
—
Shares disposed
11.7K
Cash buys
—
Cash sales
6.00
Net activity
-11,651
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Izraeli Tomer | Director / Officer | S-Sale | D | Ordinary Shares | 500 | 11.85 | 5.9K | 31,512 | D | ↗ |
| 2026-03-31 | Carmel Liron | Director | S-Sale | D | Ordinary Shares | 942 | 12.36 | 11.6K | 3,127 | D | ↗ |
| 2026-03-31 | Adler Oz | Director | S-Sale | D | Ordinary Shares | 3,292 | 12.05 | 39.7K | 19,850 | D | ↗ |
| 2026-03-30 | Turgeman Tidhar | Director / Officer | S-Sale | D | Ordinary Shares | 2,917 | 10.90 | 31.8K | 17,518 | D | ↗ |
| 2026-03-30 | Izraeli Tomer | Director / Officer | S-Sale | D | Ordinary Shares | 3,900 | 10.90 | 42.5K | 32,012 | D | ↗ |
| 2026-03-30 | Carmel Liron | Director | S-Sale | D | Ordinary Shares | 100 | 11.00 | 1.1K | 4,069 | D | ↗ |
| 2026-03-18 | Vinokur Yehonatan Zalman | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 2 | D | ↗ |
| 2026-03-18 | Turgeman Tidhar | Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 18 | D | ↗ |
| 2026-03-18 | Izraeli Tomer | Director / Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 79 | D | ↗ |
| 2026-03-18 | Carmel Liron | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 2 | D | ↗ |
| 2026-03-18 | BenYosef Nir | Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 3 | D | ↗ |
| 2026-03-18 | Adler Oz | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 100 | D | ↗ |
| 2023-10-31 | Turgeman Tidhar | Officer | — | — | Option to Purchase Ordinary Shares | 7 | 26.10 | 182.70 | 0 | D | ↗ |
| 2023-07-05 | Izraeli Tomer | Director / Officer | — | — | Option to Purchase Ordinary Shares | 83 | 1,700.30 | 141.1K | 0 | D | ↗ |
| 2023-06-30 | Turgeman Tidhar | Officer | — | — | Option to Purchase Ordinary Shares | 23 | 1,700.30 | 39.1K | 0 | D | ↗ |
| 2022-03-31 | BenYosef Nir | Officer | — | — | Option to Purchase Ordinary Shares | 2 | 1,699.30 | 3.4K | 0 | D | ↗ |
| 2021-10-01 | Izraeli Tomer | Director / Officer | — | — | Option to Purchase Ordinary Shares | 5 | 1,699.30 | 8.5K | 0 | D | ↗ |
| 2021-06-20 | Turgeman Tidhar | Officer | — | — | Option to Purchase Ordinary Shares | 12 | 1,018.30 | 12.2K | 0 | D | ↗ |
Executive team
Top executives
Shares Outstanding
1.12M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Tomer Izraeli | Founder, Chief Executive Officer & Director | 365.5K | male |
| Tidhar Turgeman | Chief Technology Officer | 270.0K | — |
| Nir Ben Yosef | Chief Financial Officer & Compliance Officer | 129.0K | male |
| Eyal S. Ron | Chief Scientific Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PLRZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
